Stratrix
On the Record · Bausch Health Companies

Bausch Health Companies acquisitions, on the record

The businesses Bausch Health Companies bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

BusinessDealWhenValue
XIIDRA ® (lifitegrast ophthalmic solution) and certain other ophthalmology assets from Novartis Pharma AG and Novartis Finance Corporation
Word for word“Bausch + Lomb has recently completed a number of acquisitions and in-licensing transactions, including the recent acquisition of XIIDRA ® (lifitegrast ophthalmic solution) and certain other ophthalmology assets from Novartis Pharma AG and Novartis Finance Corporation (the “XIIDRA Acquisition”).” 10-K for 2023
acquisition——
AcuFocus, Inc.
Word for word“During January 2023, Bausch + Lomb acquired AcuFocus, Inc. (“AcuFocus”), an ophthalmic medical device company that has delivered breakthrough small aperture intraocular technology to address the diverse unmet needs in eye care.” 10-K for 2023
acquisitionDuring January 2023—
Total Titanium Inc.
Word for word“During December 2022, Bausch + Lomb acquired Total Titanium Inc., an ophthalmic microsurgical instrument and machined parts manufacturing company.” 10-K for 2023
acquisitionDuring December 2022—
Paragon BioTeck, Inc.
Word for word“During November 2022, Bausch + Lomb acquired Paragon BioTeck, Inc. (“Paragon BioTeck”), an eye-care focused drug development company, having a primary emphasis on the early detection of ocular diseases.” 10-K for 2023
acquisitionDuring November 2022—
Amoun Pharmaceutical Company S.A.E. (“Amoun”)
Word for word“To date, we received approximately $4,100 million in net proceeds from these divestitures, which includes the sale of Amoun Pharmaceutical Company S.A.E. (“Amoun”) discussed below.” 10-K for 2023
divestiture—approximately $4,100 million in net proceeds from these divestitures
Sprout Pharmaceuticals subsidiary
Word for word“In addition, as was the case with our sale of our Sprout Pharmaceuticals subsidiary, we may recognize a loss on sale in connection with such divestitures.” 10-K for 2023
divestiture——
XIIDRA
Word for word“Bausch + Lomb completed the acquisition of XIIDRA ® during the third quarter of 2023.” 10-K for 2024
acquisitionThird quarter of 2023—
Whitecap Biosciences LLC
Word for word“In January 2025, Bausch + Lomb acquired Whitecap Biosciences LLC, (“Whitecap Biosciences”).” 10-K for 2024
acquisitionIn January 2025—
Elios Vision, Inc.
Word for word“In December 2024, Bausch + Lomb acquired Elios Vision, Inc. (“Elios Vision”).” 10-K for 2024
acquisitionIn December 2024—
TearLab Corporation, d/b/a Trukera Medical
Word for word“In July 2024, Bausch + Lomb acquired TearLab Corporation, d/b/a Trukera Medical (“Trukera Medical”) a U.S.-based privately held ophthalmic medical diagnostic company.” 10-K for 2024
acquisitionIn July 2024—
XIIDRA and certain other ophthalmology assets from Novartis
Word for word“In September 2023, Bausch + Lomb acquired XIIDRA ® , the first and only non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets from Novartis Pharma AG and Novartis Finance Corporation (together with Novartis Pharma AG, “Novartis”) (the “XIIDRA Acquisition”).” 10-K for 2024
acquisitionIn September 2023—
Obagi Medical Products business
Word for word“We have completed a number of divestitures of our assets, products or businesses that were not considered core to our ongoing operations or the needs of our primary-customer base, including the divestitures of our Obagi Medical Products business, our iNova Pharmaceuticals business, our Dendreon Pharmaceuticals subsidiary, our Sprout Pharmaceuticals subsidiary, the CeraVe ® , AcneFree ™ and AMBI ® skincare brands and our Amoun Pharmaceutical subsidiary.” 10-K for 2024
divestiture——
Wuhan Shibo Zhenmei Technology Co., Ltd.
Word for word“In December 2025, we completed the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd. (“Shibo Zhenmei”), consisting of the aesthetics distribution business of our full‑service distributor in China, the Shibo Group.” 10-K for 2025
acquisitionDecember 2025—
DURECT Corporation
Word for word“In September 2025, we acquired DURECT, a biopharmaceutical company engaged in the development of epigenetic therapies that target dysregulated deoxyribonucleic acid methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury.” 10-K for 2025
acquisitionSeptember 2025—
As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedCash paid for acquisitions (net of cash acquired)Goodwill from acquisitions
2016-12-31$19 million$1 million
2017-12-31$0—
2018-12-31−$5 million—
2019-12-31$180 million$3 million
2020-12-31$0—
2021-12-31$0—
2022-12-31$45 million$5 million
2023-12-31$1.89 billion$31 million
2024-12-31—$29 million
2025-12-31—$119 million

Deal filings since 2016

Read from Bausch Health Companies’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-19. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.